SCHEMBL22062616

SCHEMBL22062616

c1ccc(-c2ccc(-c3c4ccccc4c(-c4ccc(-c5cccc6oc7ccccc7c56)cc4)c4ccccc34)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ PTPN1 P18031 3/20 0.39
▸ CDC14B O60729 3/20 0.39
▸ CDC14A Q9UNH5 3/20 0.39
▸ PLA2G2A P14555 5/20 0.39
▸ PLA2G4A P47712 5/20 0.39
▸ BACE1 P56817 1/20 0.38
▸ ALOX5 P09917 1/20 0.38
▸ CYP3A4 P08684 2/20 0.37
▸ HPGD P15428 2/20 0.37
▸ MAOA P21397 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ MAPT P10636 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ GLA P06280 1/20 0.37
▸ PGAM1 P18669 1/20 0.37
▸ CASP1 P29466 1/20 0.37
▸ CASP7 P55210 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17917504 0.98 CA1 (0.42) CA1CA2PTPN1CDC14BCDC14A
SCHEMBL22062618 0.94 PLA2G2A (0.44) CA1CA2PTPN1CDC14BCDC14A
SCHEMBL27341252 0.94 CA1 (0.40) CA1CA2PTPN1CDC14BCDC14A
SCHEMBL22063086 0.94 CA1 (0.40) CA1CA2PTPN1CDC14BCDC14A
SCHEMBL22854772 0.93 CA1 (0.41) CA1CA2PTPN1CDC14BCDC14A
SCHEMBL18382893 0.93 CA1 (0.41) CA1CA2PTPN1CDC14BCDC14A
SCHEMBL21811019 0.93 PLA2G2A (0.42) CA1CA2CDC14BCDC14APLA2G2A
SCHEMBL25624626 0.93 PLA2G2A (0.43) CA1CA2PTPN1CDC14BCDC14A
SCHEMBL25624624 0.93 PLA2G2A (0.43) CA1CA2PTPN1CDC14BCDC14A
SCHEMBL22706259 0.92 ALOX5 (0.41) CA1CA2CDC14BCDC14APLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11665962-B2 Organic electroluminescence element and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2023-05-30 — — US disclosed
US-11665962-B2 Organic electroluminescence element and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2023-05-30 — — US disclosed
US-20210384445-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2021-12-09 — — US disclosed
US-20210320251-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPLIANCE IDEMITSU KOSAN CO.,LTD. (JP) 2021-10-14 — — US disclosed
US-20200212315-A1 ORGANIC ELECTROLUMINESCENT ELEMENT, ELECTRONIC DEVICE, AND COMPOUND IDEMITSU KOSAN CO.,LTD. (JP) 2020-07-02 — — US disclosed
US-20200185620-A1 COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2020-06-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210320251-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC APPLIANCE OLA1, TAS2R19, TMEM109 CA1 2506/4885CA2 876/4885PTPN1 3645/4885
US-20200212315-A1 ORGANIC ELECTROLUMINESCENT ELEMENT, ELECTRONIC DEVICE, AND COMPOUND OR10J3, ESR1, NFE2L2 CA1 2114/4885CA2 1869/4885PTPN1 4663/4885
US-20210384445-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE ESR1, EML4, L1CAM CA1 2363/4885CA2 2796/4885PTPN1 4353/4885
US-20200185620-A1 COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE EMC2, NFE2L2, AOC2 CA1 3331/4885CA2 1915/4885PTPN1 4335/4885
US-11665962-B2 Organic electroluminescence element and electronic device ESR1, EML4, L1CAM CA1 2363/4885CA2 2796/4885PTPN1 4353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback